Drug-Induced Angioedema

News

FDA, Kalvista and Hereditary Angioedema

After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.

InvestorsHub on MSN · 1d

KalVista Shares Surge Following FDA Nod for First Oral Hereditary Angioedema Treatment

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) saw its stock soar by 19% after receiving FDA approval for EKTERLY (sebetralstat)—the first oral, on-demand treatment for hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition.

The American Journal of Manage… · 1d

FDA Approves Sebetralstat for Hereditary Angioedema

For the second time in under 3 weeks, the FDA has approved treatment for the inherited genetic disorder characterized by recurrent episodes of severe swelling.

clinicaladvisor.com9mon

What to look for with drug-induced urticaria - Clinical Advisor

Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and ...

Hosted on MSN3mon

7 Drugs That Can Cause a Rash (and How to Identify a Skin Reaction) - MSN

Medically reviewed by Femi Aremu, PharmD Skin rashes can have many different causes, one of which is medications. The symptoms of drug-induced skin reactions can range from a mild itchy rash to ...

Science Daily1y

Drug-induced skin swelling - ScienceDaily

Drug-induced skin swelling Bonn researchers identify novel risk locus in the genome for ACE inhibitor-induced angioedema Date: January 31, 2024 Source: ...

Medscape6mon

Bupropion-induced Angioedema - Page 3 - Medscape

In the product labeling, angioedema is documented as a possible, but rare, ADR, occurring at a rate of 0.1–0.3%, with symptoms usually developing between 10 and 20 days after initiation of the ...

BioSpace1d

KalVista Wins OK for First On-Demand Hereditary Angioedema Pill

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

Leading Factor Driving The Angioedema Treatment Market In 2025: Rise In Rare Disease Diagnoses Fueling The Growth

Angioedema Treatment Global Market Report 2025. The Business Research Company's Angioedema Treatment Global Market Report 2025 – Market Size, Trends, And ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results